Interview Questions for Thoracic Oncology and Multimodality Treatment Planning

Lung cancer staging uses a system to describe the extent of the cancer, crucial for treatment planning and prognosis. The most common system is the TNM system, where:

• T (Tumor): Describes the size and location of the primary tumor (e.g., T1, T2, T3, T4, with T1 being the smallest and T4 the largest or most invasive).
• N (Nodes): Indicates the involvement of regional lymph nodes (e.g., N0, N1, N2, N3, with N0 meaning no lymph node involvement and N3 indicating extensive lymph node spread).
• M (Metastasis): Specifies whether the cancer has spread to distant organs (e.g., M0 meaning no distant metastasis, M1 meaning distant metastasis is present).

These three components are combined to determine the overall stage (e.g., Stage I, Stage II, Stage III, Stage IV), reflecting the cancer’s aggressiveness and prognosis. Stage I cancers are typically localized, while Stage IV indicates widespread disease. The TNM staging system is constantly refined based on evolving knowledge and research. For example, the precise location of lymph node involvement and specific molecular characteristics are now increasingly incorporated into staging for more personalized treatment strategies.

Surgery plays a vital role in treating early-stage NSCLC (Non-Small Cell Lung Cancer). The goal is complete resection – removal of the entire tumor and a margin of surrounding healthy tissue. The type of surgery depends on the tumor’s location and size. For instance, a lobectomy involves removing a lobe of the lung, while a pneumonectomy removes an entire lung. Minimally invasive techniques, like video-assisted thoracoscopic surgery (VATS), are increasingly used, offering patients quicker recovery times and reduced scarring. Surgical success depends on many factors, including the patient’s overall health, the stage of the cancer, and the surgeon’s expertise. Post-surgery, patients may undergo adjuvant therapy (additional treatment like chemotherapy or radiation) to further reduce the risk of recurrence. For instance, a patient with stage II NSCLC might undergo a lobectomy followed by adjuvant chemotherapy.

Radiation therapy uses high-energy radiation to kill cancer cells. Its role in lung cancer treatment is multifaceted:

• Curative Intent: In early-stage NSCLC that is not surgically resectable (unable to be completely removed by surgery), or in cases where surgery is too risky for the patient, radiation can be used to deliver a curative dose to the tumor.
• Adjuvant Therapy: After surgery, radiation is often used as adjuvant therapy to eliminate any remaining microscopic cancer cells and reduce the risk of recurrence. This is particularly important in patients with lymph node involvement.
• Neoadjuvant Therapy: Before surgery, radiation can be used to shrink large tumors, making them easier to remove surgically (neoadjuvant chemoradiation).
• Palliative Care: For advanced-stage lung cancer where cure is not possible, radiation can help alleviate symptoms like pain, bleeding, or airway obstruction, improving quality of life.
• Stereotactic Body Radiation Therapy (SBRT): This advanced technique delivers high doses of radiation in a few sessions, precisely targeting the tumor while minimizing damage to surrounding tissues. This is increasingly used for early-stage, small tumors.

The decision to use radiation therapy is made on a case-by-case basis, considering the patient’s overall health, stage of cancer, and other factors.

Chemotherapy regimens for NSCLC vary based on several factors, including stage, histology (cell type), and patient characteristics. Commonly used drugs include:

• Platinum-based agents: Cisplatin and carboplatin are often the cornerstone of NSCLC chemotherapy, frequently combined with other drugs.
• Taxanes: Paclitaxel and docetaxel are microtubule inhibitors that interfere with cell division.
• Alkylating agents: Gemcitabine and pemetrexed disrupt DNA synthesis.
• Targeted therapies: Drugs targeting specific molecular abnormalities in cancer cells (e.g., EGFR, ALK, ROS1 inhibitors) are now frequently used based on the results of biomarker testing.

Examples of common regimens include:

• Cisplatin + Gemcitabine
• Carboplatin + Paclitaxel
• Carboplatin + Pemetrexed

The choice of regimen is carefully considered by an oncologist, who takes into account the patient’s overall health, performance status, and specific cancer characteristics, as identified through biopsies and advanced testing.

Multimodality treatment planning in thoracic oncology involves integrating different treatment approaches – surgery, radiation therapy, chemotherapy, and targeted therapy – to maximize cancer control and improve patient outcomes. The plan is highly individualized, tailored to the specific characteristics of the patient and their cancer. The key principle is to use the most effective combination of therapies to achieve the best possible results while minimizing side effects. This requires a multidisciplinary team approach, including thoracic surgeons, radiation oncologists, medical oncologists, and other specialists. Thorough discussion and careful consideration of risks and benefits are crucial aspects of the planning process.

Determining the optimal sequencing of treatment modalities is a complex process that considers numerous factors. For instance:

• Stage of Cancer: Early-stage cancers might involve surgery followed by adjuvant chemotherapy or radiation. Advanced cancers may benefit from neoadjuvant chemotherapy followed by surgery and/or radiation.
• Tumor characteristics: Molecular testing can identify specific genetic alterations guiding targeted therapy and informing the sequencing of treatments.
• Patient factors: The patient’s overall health, age, performance status, and comorbidities significantly influence the treatment approach and sequencing.
• Treatment feasibility: Certain treatment combinations may be contraindicated or too toxic for certain patients.

Multidisciplinary tumor boards, where specialists from different fields discuss individual cases, are essential for optimal sequencing decisions. The goal is to develop a treatment strategy that optimizes cancer control and minimizes toxicity, considering the patient’s unique needs and preferences throughout the entire process.

Radiation therapy to the thorax can cause various side effects, impacting different organ systems. These may include:

• Respiratory: Cough, shortness of breath, pneumonitis (lung inflammation), radiation-induced lung injury.
• Cardiovascular: Pericarditis (inflammation of the sac surrounding the heart), myocarditis (inflammation of the heart muscle).
• Esophageal: Esophagitis (inflammation of the esophagus), dysphagia (difficulty swallowing).
• Skin: Erythema (redness), dryness, desquamation (skin peeling).
• Fatigue: A very common side effect of cancer treatment.

The severity of these side effects varies depending on the radiation dose, treatment technique, and individual patient factors. Close monitoring during and after radiation treatment is essential, along with supportive care to manage side effects and improve patient comfort and quality of life. For instance, medications to manage pain, nausea, and inflammation might be prescribed. The radiation oncologist will carefully plan the treatment to minimize these side effects as much as possible while still providing effective cancer treatment.

Managing chemotherapy toxicities in lung cancer patients is crucial for ensuring treatment efficacy and improving their quality of life. Toxicity profiles vary depending on the specific chemotherapy regimen used, but common side effects include fatigue, nausea, vomiting, mucositis (mouth sores), neutropenia (low white blood cell count increasing infection risk), and thrombocytopenia (low platelet count increasing bleeding risk).

My approach involves proactive management. This begins with a thorough discussion with the patient about potential side effects before treatment starts, setting realistic expectations. We utilize pre-emptive measures like anti-emetics (for nausea), growth factors (to stimulate white blood cell production), and meticulous oral care to minimize mucositis. Regular blood tests monitor blood counts, allowing for timely intervention if counts fall dangerously low. Dose adjustments or treatment breaks may be necessary to manage toxicity, a decision made in close consultation with the patient considering the balance between the risk of side effects and the potential benefit of the therapy. For instance, a patient experiencing severe neutropenia might require a temporary delay in chemotherapy, allowing their immune system to recover before resuming treatment. We also work closely with supportive care specialists, including nurses, pharmacists, and dieticians, to address other symptoms like fatigue and malnutrition.

Finally, open communication is key. Patients are encouraged to report any side effects immediately, no matter how minor they might seem. This allows for prompt identification and management of problems, preventing minor issues from escalating into serious complications.

Targeted therapy has revolutionized the treatment landscape for lung cancer, particularly in patients with specific genetic mutations. My experience encompasses the use of tyrosine kinase inhibitors (TKIs) like EGFR inhibitors (gefitinib, erlotinib, afatinib) for patients with EGFR-mutated non-small cell lung cancer (NSCLC) and ALK inhibitors (crizotinib, alectinib) for those with ALK rearrangements. I’ve also utilized other targeted agents, such as BRAF and HER2 inhibitors for their respective mutations.

The selection of targeted therapy is personalized based on comprehensive molecular testing of the tumor biopsy. Once the mutation is identified, we can tailor the therapy to that specific abnormality. For example, a patient with an EGFR exon 19 deletion would likely benefit from an EGFR TKI. Regular imaging scans are essential to monitor response and detect resistance, as tumors can eventually develop resistance mechanisms against targeted therapies. When resistance develops, I have experience exploring second- and third-generation TKIs, or exploring other treatment options like chemotherapy or immunotherapy.

A crucial aspect is managing the side effects associated with targeted therapies. These can include skin rash, diarrhea, and liver toxicity. Careful monitoring and management of these toxicities are critical to ensure patients can tolerate and benefit from the treatment.

The management of small cell lung cancer (SCLC) is highly aggressive due to its rapid growth and tendency to metastasize early. Current guidelines generally recommend a multimodal approach, combining chemotherapy with radiation therapy.

For limited-stage SCLC (confined to one lung and nearby lymph nodes), concurrent chemoradiotherapy (chemotherapy given at the same time as radiation) is the standard of care. This approach aims to eradicate the disease locally while simultaneously controlling systemic spread. Extensive-stage SCLC (spread beyond one lung or mediastinum), on the other hand, typically involves chemotherapy as the initial treatment. Following this, if the patient has responded well, they may be considered for consolidation radiotherapy to the area of primary tumor or sites of metastatic disease.

Immunotherapy agents, like immune checkpoint inhibitors, are increasingly being incorporated into SCLC treatment regimens, especially in the setting of extensive-stage disease, often in combination with chemotherapy. The specific choice of chemotherapeutic agents and sequencing of treatments depend on multiple factors including performance status, comorbidities, and specific tumor characteristics. Regular monitoring with imaging scans and blood tests remains vital throughout the treatment and follow-up period to assess response and detect recurrence. Patients with recurrent or progressive disease might be offered further lines of chemotherapy or immunotherapy depending on their condition and the availability of appropriate clinical trials.

Immunotherapy harnesses the body’s own immune system to fight cancer cells. In lung cancer, this involves checkpoint inhibitors that block proteins that prevent immune cells from attacking tumor cells. Two major classes are anti-PD-1 (e.g., pembrolizumab, nivolumab) and anti-PD-L1 (e.g., atezolizumab, durvalumab) antibodies.

My experience indicates that immunotherapy has dramatically changed the treatment landscape for lung cancer, particularly for patients with advanced NSCLC. The use of immunotherapy is often guided by PD-L1 expression on tumor cells or, in the case of some trials, by tumor mutational burden (TMB), which measures the overall number of mutations in the tumor DNA. A high tumor mutational burden correlates with increased responsiveness to immune checkpoint inhibitors.

Immunotherapy is administered intravenously. Common side effects, termed immune-related adverse events (irAEs), include rash, fatigue, diarrhea, and pneumonitis (lung inflammation). Careful monitoring for irAEs and prompt intervention with corticosteroids or other immunosuppressive medications are vital. The decision to use immunotherapy versus other treatments often involves a multidisciplinary discussion with the patient, carefully weighing the potential benefits and risks.

Assessing a patient’s fitness for surgery, a crucial step in lung cancer treatment, involves a comprehensive evaluation going beyond just the tumor itself. The goal is to ensure that the patient can safely tolerate the procedure and recover successfully while achieving the therapeutic benefit of surgery.

My assessment involves a thorough review of their medical history, including cardiac, pulmonary, and renal function. This includes reviewing electrocardiograms (ECGs), chest X-rays, pulmonary function tests (PFTs), and blood work. The PFTs are especially crucial, as they assess the patient’s lung capacity and ability to tolerate lung resection. A detailed physical examination and potentially cardiac stress testing are also performed. Factors considered include the patient’s age, overall health status, functional capacity (measured by activities of daily living), and comorbidities such as diabetes, hypertension, or chronic obstructive pulmonary disease (COPD).

A multidisciplinary approach is critical. Collaboration with anesthesiologists, cardiologists, and respiratory therapists helps to determine surgical suitability. If a patient has significant comorbid conditions, a prehabilitation program focusing on improving respiratory and cardiac fitness before surgery may be implemented to enhance their ability to safely undergo the procedure and recover faster. A patient’s decision-making capacity, understanding of the risks and benefits, and emotional support network also form part of the overall assessment.

Brachytherapy, the placement of radioactive sources directly into or near a tumor, has a limited role in thoracic oncology compared to other treatment modalities. However, it can be highly effective in specific situations, mostly for palliation of symptoms.

My experience with brachytherapy in thoracic oncology primarily involves its use in managing locally advanced inoperable lung cancers where surgery or external beam radiotherapy might not be feasible. It may be used for patients experiencing severe symptoms like airway obstruction or bleeding. In such cases, brachytherapy can help to reduce tumor bulk, relieve airway compression, and improve quality of life. We might also employ it for the palliative management of chest wall recurrences following prior treatment, aiming to reduce local pain and improve comfort.

The procedure is typically performed under fluoroscopic guidance or CT guidance, allowing precise placement of the radioactive sources to deliver a targeted dose to the tumor while minimizing radiation exposure to surrounding healthy tissues. A careful assessment of the patient’s clinical situation and tumor location is essential to determine suitability for brachytherapy. Post-procedure monitoring includes assessment of radiation toxicity and symptom relief. This is a less frequently utilized technique, but in appropriately selected patients, it can offer significant benefits in terms of symptom control and quality of life improvement.

Selecting the optimal radiation treatment technique for lung cancer involves considering several key factors aimed at maximizing tumor control while minimizing damage to surrounding healthy tissues. The goal is to deliver a sufficient radiation dose to the tumor to kill cancer cells, without causing unacceptable side effects to the heart, lungs, esophagus, or spinal cord.

Factors influencing the choice include:

• Tumor location and size: Tumors near critical structures may require highly conformal techniques like intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) to precisely target the tumor while sparing adjacent organs.
• Patient anatomy and respiratory motion: Techniques like 4D-CT simulation and respiratory gating are used to account for tumor movement during breathing, improving target coverage and reducing dose to normal tissues. Deep inspiration breath hold (DIBH) is another technique used to reduce the dose to the heart during radiation to the left lung.
• Disease stage and treatment goals: Curative-intent radiotherapy generally necessitates higher doses, demanding precise targeting. Palliative radiotherapy aims to alleviate symptoms with potentially lower doses and simpler techniques.
• Overall health status and comorbidities: A patient’s ability to tolerate radiation treatment influences the choice of technique and the fractionation schedule.
• Availability of technology and expertise: Access to advanced technologies, as well as the expertise of the radiation oncology team, plays a critical role in selecting the most appropriate method.

For instance, a centrally located tumor near the heart and great vessels might necessitate IMRT or VMAT with careful dose constraints to minimize cardiac toxicity. In contrast, a smaller, peripherally located tumor in a patient with good overall health might be treated with 3D-conformal radiotherapy (3D-CRT), providing a balance between efficacy and convenience.

Palliative care isn’t just for end-of-life; it’s a crucial part of cancer treatment from diagnosis onwards. It focuses on improving quality of life by addressing physical, emotional, and spiritual symptoms. We integrate it by having conversations early about patient goals and preferences, which might include pain management, symptom relief, emotional support, and spiritual guidance. For example, a patient might prioritize maintaining their independence and enjoying time with loved ones. We’d tailor treatment to minimize side effects that could interfere with these goals, perhaps using less aggressive chemotherapy regimens or focusing on targeted therapies with fewer side effects. We collaborate closely with palliative care specialists to manage symptoms such as shortness of breath, pain, and fatigue proactively.

This approach isn’t about giving up on treatment; it’s about optimizing both treatment efficacy and patient well-being. We continually assess the patient’s response and adjust the palliative care plan as needed throughout the treatment journey.

Image-guided radiotherapy (IGRT) is transformative in thoracic oncology. It allows us to precisely target tumors, minimizing damage to surrounding healthy tissues. My experience encompasses various IGRT techniques, including CT-based image guidance and cone-beam CT (CBCT) for daily verification of tumor position. We use this technology for both external beam radiotherapy (EBRT) and brachytherapy. For instance, in treating a patient with a centrally located lung tumor near the heart, IGRT enables us to deliver a high dose of radiation to the tumor while sparing the heart, thereby reducing the risk of cardiac toxicity. The precision of IGRT is particularly critical in cases of moving targets, such as tumors in the upper lobes of the lungs, which can shift during breathing. We often employ techniques like deep inspiration breath hold (DIBH) or gated radiotherapy to minimize these movement-related challenges.

Treating elderly lung cancer patients presents unique challenges due to their increased risk of comorbidities like heart disease, kidney dysfunction, and frailty. Their decreased physiological reserve means they may tolerate treatment less well than younger patients. We need a very individualized approach. We carefully assess their performance status using tools like the Eastern Cooperative Oncology Group (ECOG) performance status scale. This helps us determine the intensity of therapy they can safely handle. It might mean selecting less toxic treatment regimens, adjusting dosages, or even opting for supportive care alone in some cases. Geriatric assessment is crucial to identify and manage potential problems before they become serious. We also consider their frailty and other co-morbidities in choosing appropriate treatments. For example, if a patient has significant heart problems, we might avoid chemotherapy regimens that are known to be cardiotoxic.

Metastatic lung cancer requires a multidisciplinary approach. The goal shifts from curative intent to palliative management, focusing on controlling disease progression, extending survival, and enhancing quality of life. We use systemic therapies, such as chemotherapy, targeted therapy, or immunotherapy, tailored to the specific molecular profile of the tumor. This often involves molecular testing to identify driver mutations like EGFR, ALK, ROS1, and BRAF, which can guide the selection of targeted therapies. For example, if a patient has an EGFR mutation, we would likely initiate treatment with an EGFR tyrosine kinase inhibitor. Radiation therapy might be used for palliative purposes, such as to relieve pain from bone metastases or to treat brain metastases. Close monitoring of disease progression is essential, and we may adjust treatment based on response and the emergence of side effects.

Shared decision making with the patient and their family is paramount, ensuring alignment with their goals and values.

Staying abreast of clinical trials is vital in thoracic oncology because the field is constantly evolving. I actively participate in reviewing and selecting appropriate clinical trials for my patients. My knowledge spans various trial phases, from early-phase trials investigating novel agents to larger, phase III trials comparing standard therapies to new interventions. I assess each patient’s eligibility based on factors such as tumor type, stage, performance status, and molecular profile. Crucially, I have thorough discussions with patients to explain the potential benefits and risks of participating, ensuring they make informed decisions. I am familiar with databases like ClinicalTrials.gov and actively seek out trials sponsored by the National Cancer Institute (NCI) and other reputable organizations.

Communicating complex medical information effectively is paramount. I use a patient-centered approach, tailoring my language and explanation to the individual’s level of understanding. I avoid using jargon whenever possible, and I actively encourage patients to ask questions. I often use visual aids, such as diagrams or models, to illustrate concepts. I emphasize active listening, validating the patient’s emotions and concerns. When discussing treatment options, I explain the benefits, risks, and likelihood of success in a clear, concise manner. I also involve family members as needed, particularly when dealing with complex decisions. I believe effective communication is not just about conveying information; it’s about building a strong therapeutic relationship based on trust and mutual respect. For families grappling with a diagnosis, I prioritize empathy and clear, compassionate communication.

Molecular testing is fundamental to personalized medicine in lung cancer. My experience includes ordering and interpreting various tests, including next-generation sequencing (NGS) panels to detect driver mutations, immunohistochemistry (IHC) to assess PD-L1 expression, and fluorescence in situ hybridization (FISH) to detect gene rearrangements. For example, the presence of an EGFR mutation guides us toward the use of EGFR tyrosine kinase inhibitors, while a high PD-L1 expression suggests immunotherapy might be beneficial. I understand the implications of these results and how they influence treatment selection and prognosis. I also discuss the limitations of testing and the need for clinical correlation in making treatment decisions. The evolving landscape of molecular testing requires continuous professional development to stay updated with the latest technologies and their clinical implications.

Interpreting imaging studies like CT and PET scans in thoracic oncology is crucial for accurate diagnosis, staging, and treatment planning. We look for several key features.

• CT scans provide detailed anatomical information, revealing the size, location, and extent of lung tumors, lymph node involvement (mediastinal and hilar), and the presence of pleural or pericardial effusions. We assess for invasion into adjacent structures like the chest wall, great vessels, or spine. For example, a CT scan might show a 3cm mass in the right upper lobe with involvement of the right hilar lymph nodes, suggesting a more advanced stage.
• PET scans offer functional information, showing metabolic activity of the tumor. Areas of increased glucose uptake (FDG avidity) indicate active tumor cells, helping to distinguish between benign and malignant lesions, assess response to therapy, and detect distant metastases. A PET scan might show intense FDG uptake in the primary lung tumor, but also reveal metastatic disease in the bones or brain, significantly impacting treatment strategies.

Combining CT and PET scans provides a comprehensive picture. We use standardized staging systems like the TNM system (Tumor, Node, Metastasis) to classify the extent of the disease based on this imaging information, which guides treatment decisions.

Managing pleural effusions, the buildup of fluid around the lungs, is a common challenge in thoracic oncology. The approach depends on the cause and the patient’s clinical condition.

• Diagnostic thoracentesis: This procedure involves inserting a needle into the pleural space to remove fluid for cytologic analysis, determining if the effusion is malignant (cancer cells present), exudative (infection or inflammation), or transudative (heart failure).
• Therapeutic thoracentesis: If the effusion is causing significant respiratory compromise, repeated thoracentesis can relieve pressure. This is often a temporary solution.
• Pleurodesis: This procedure aims to permanently seal the pleural space, preventing fluid reaccumulation. It involves injecting a sclerosing agent (e.g., talc) into the pleural cavity, inducing inflammation and adhesion.
• Indwelling pleural catheters: These catheters allow for repeated drainage of fluid, offering a less invasive alternative to repeated thoracentesis, especially for patients with recurrent effusions.

In patients with malignant pleural effusions, treatment is often palliative, focusing on symptom relief. The choice of management strategy depends on individual factors such as the patient’s overall health, performance status, and the prognosis.

The multidisciplinary team (MDT) in thoracic oncology is essential for optimal patient care. It involves a collaborative approach, bringing together specialists with diverse expertise to create a personalized treatment plan.

• Pulmonologists: Manage medical aspects of lung disease.
• Thoracic surgeons: Perform surgical procedures (e.g., lobectomy, pneumonectomy).
• Medical oncologists: Administer chemotherapy and targeted therapies.
• Radiation oncologists: Deliver radiation therapy.
• Pathologists: Analyze tissue samples to confirm diagnosis and guide treatment selection.
• Radiologists: Interpret imaging studies.
• Respiratory therapists: Provide pulmonary rehabilitation and support.
• Oncology nurses: Provide patient education, administer treatment, and manage side effects.

The MDT meets regularly to discuss individual cases, weigh the benefits and risks of different treatment options, and reach a consensus on the best approach for each patient. This collaborative approach ensures that patients receive the most comprehensive and appropriate care.

Staying updated in the rapidly evolving field of thoracic oncology requires a multifaceted approach:

• Professional journals and publications: I regularly read journals such as the Journal of Clinical Oncology, the Journal of Thoracic Oncology, and the Annals of Oncology to stay abreast of the latest research findings and clinical trials.
• Medical conferences and meetings: Attending national and international conferences allows for interaction with leading experts, learning about cutting-edge treatments, and networking with colleagues.
• Continuing medical education (CME) courses: Engaging in CME courses keeps my knowledge and skills up-to-date and ensures compliance with professional standards.
• Online resources and databases: Utilizing reputable online resources and databases like PubMed and UpToDate provides access to a vast amount of medical literature and clinical guidelines.
• Participation in clinical trials: Active involvement in research and clinical trials allows me to contribute to the advancement of the field and gain hands-on experience with innovative therapeutic strategies.

This continuous learning process allows me to provide my patients with the most advanced and evidence-based care.

One particularly challenging case involved a 68-year-old patient with a large, centrally located lung tumor invading the major airway. Surgery was deemed high-risk due to the proximity to critical vascular structures and potential for significant postoperative complications. The tumor was also causing significant airway obstruction, leading to respiratory distress.

Our MDT discussed various options, including surgery, radiation therapy, and chemotherapy. Given the patient’s age and the high surgical risk, we opted for a multimodality approach. We started with stereotactic body radiation therapy (SBRT) to reduce the tumor size and improve airway patency. This was followed by concurrent chemoradiotherapy to maximize tumor control. Regular monitoring with imaging studies ensured the treatment was effective and allowed for early detection of any complications.

This approach proved successful in stabilizing the patient’s condition and significantly improving their quality of life. Although complete eradication of the tumor wasn’t achieved, we managed to control the disease and minimize its impact on the patient’s respiratory function. This highlights the importance of individualized treatment planning and the collaborative efforts of a multidisciplinary team in tackling complex cases in thoracic oncology.

My salary expectations are commensurate with my experience, expertise, and the market rate for a thoracic oncologist with my qualifications in a similar setting. I am open to discussing a competitive compensation package that reflects the value I bring to the organization.